Replies to post #164211 on Cytodyn Inc (CYDY)

[DonDonDonDon]

Fair, but it was a combined trial. We do not know the demand/ratio of critical or severe that was available. Maybe there were more critical that wanted to get in, but the design only allowed a specific amount. With them being separate, they can go as fast as the demand of critical/severe are available (that meets the trial criteria). Probably the reason they are separated.

The trials might be technically separated but the severe and critical patients will be in the same ICUs. So most patients will get leronlimab when severe. Most of the patients who take leronlimab when critical will be patients who were transferred from a different hospital while already critical or close to critical.